enGene (NASDAQ:ENGN – Get Free Report) is one of 453 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare enGene to related businesses based on the strength of its dividends, earnings, profitability, valuation, analyst recommendations, risk and institutional ownership.
Profitability
This table compares enGene and its rivals’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
enGene | N/A | -63.25% | -5.65% |
enGene Competitors | -11,521.49% | -124.77% | -24.97% |
Risk and Volatility
enGene has a beta of -0.63, indicating that its share price is 163% less volatile than the S&P 500. Comparatively, enGene’s rivals have a beta of 1.23, indicating that their average share price is 23% more volatile than the S&P 500.
Dividends
Valuation and Earnings
This table compares enGene and its rivals top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
enGene | N/A | $104.74 million | -3.23 |
enGene Competitors | $157.40 million | -$18.68 million | 80.37 |
enGene’s rivals have higher revenue, but lower earnings than enGene. enGene is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Insider and Institutional Ownership
64.2% of enGene shares are owned by institutional investors. Comparatively, 31.5% of shares of all “Biotechnology” companies are owned by institutional investors. 13.7% of enGene shares are owned by company insiders. Comparatively, 22.5% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Analyst Ratings
This is a summary of recent recommendations and price targets for enGene and its rivals, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
enGene | 0 | 0 | 6 | 0 | 3.00 |
enGene Competitors | 751 | 2459 | 5797 | 67 | 2.57 |
enGene presently has a consensus price target of $34.40, indicating a potential upside of 553.99%. As a group, “Biotechnology” companies have a potential upside of 17.62%. Given enGene’s stronger consensus rating and higher possible upside, equities analysts plainly believe enGene is more favorable than its rivals.
Summary
enGene beats its rivals on 10 of the 15 factors compared.
enGene Company Profile
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.